Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related)

References

• Verma MK, Sobha K. Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects. Inflamm Res 2015;64:647-59
   PubMed Web of Science ®Google Scholar
• Kiltz U, van der Heijde D. Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clin Exp Rheumatol 2009;27(4Suppl55):S108-S11
   Web of Science ®Google Scholar
• Gonzalez A, Kremers HM, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-7
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. CG79, February 2009. Available at: https://www.nice.org.uk/guidance/cg79 [Last accessed 19 March 2015]
   Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108
   PubMed Web of Science ®Google Scholar
• Treharne GJ, Lyons AC, Hale ED, et al. ‘Compliance’ is futile but is ‘concordance’ between rheumatology patients and health professionals attainable? Rheumatology 2006;45:1-5
   PubMed Web of Science ®Google Scholar
• Belcon MC, Haynes RB, Tugwell P. A critical review of compliance studies in rheumatoid arthritis. Arthritis Rheum 1984;27:1227-33
   PubMed Web of Science ®Google Scholar
• Shi L, Hudges M, Yurgin N, Boye KS. Impact of dose frequency on compliance and health outcomes: a literature review (1996–2006). Expert Rev Pharmacoecon Outcomes Res 2007;7:187-202
   PubMedGoogle Scholar
• Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009;25:1365-77
   PubMed Web of Science ®Google Scholar
• Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011;86:304-14
   PubMed Web of Science ®Google Scholar
• Blamey R, Jolly K, Greenfield S, Jobanputra P. Patterns of analgesic use, pain and self-efficacy: a cross-sectional study of patients attending a hospital rheumatology clinic. BMC Musculoskelet Disord 2009;10:137
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, Negoescu A, Fitzpatrick JD, et al. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol 2014;33:609-14
   PubMed Web of Science ®Google Scholar
• Alivernini S, Mazzotta D, Zoli A, Ferraccioli G. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis. Retrospective analysis of safety and adherence to treatment. Drugs Aging 2009;26:395-402
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Chung CP, Arborgast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45(10Suppl2):S66-S76
   Web of Science ®Google Scholar
• van den Bemt BJ, van Lankveld WG. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheumatol 2007;3:681
   PubMedGoogle Scholar
• El Miedany Y, El Gaafary M, Palmer D. Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study. Rheumatol Int 2012;32:3061-8
   PubMed Web of Science ®Google Scholar
• van der Vaart R, Drossaert CHC, Taal E, et al. Impact of patient-accessible electronic medical records in rheumatology: use, satisfaction and effects on empowerment among patients. BMC Musculoskelet Disord 2014;15:102
   PubMed Web of Science ®Google Scholar
• Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009;65:1013-24
   PubMed Web of Science ®Google Scholar
• Perreault S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med 2009;122:647-55
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-77
   PubMed Web of Science ®Google Scholar
• Roberts AW, Crisp GD, Esserman DA, et al. Patterns of medication adherence and health care utilisation among patients with chronic disease who were enrolled in a pharmacy assistance program. N C Med J 2014;75:310-18
   PubMedGoogle Scholar
• Santoleri F, Sorice P, Lasala R, et al. Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis. J Med Econ 2014;17:320-5
   PubMedGoogle Scholar
• Pascual-Ramos V, Contreras-Yanez I. Motivations for inadequate persistence with disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective. BMC Musculoskelet Disord 2013;14:336
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Feldman DE. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis. Drugs Aging 2008;25:879-84
   PubMed Web of Science ®Google Scholar
• Curkendall S, Patel V, Gleeson M, et al. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008;59:1519-26
   PubMed Web of Science ®Google Scholar
• Contreras-Yáñez I, Cabiedes J, Villa AR, et al. Persistence on therapy is a major determinant of patient-, physician- and laboratory-reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol 2010;28:748-51
   PubMed Web of Science ®Google Scholar
• Stockl KM, Shin JS, Lew HC, et al. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. J Manag Care Pharm 2010;16:593-604
   PubMed Web of Science ®Google Scholar
• Harrold LR, Briesacher BA, Peterson D, et al. Cost-related medication nonadherence in older rheumatoid arthritis patients. J Rheumatol 2013;40:137-43
   PubMed Web of Science ®Google Scholar
• Bluett J, Morgan C, Thurston L, et al.; on behalf of BRAGGSS. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology 2015;54:494-9
   PubMed Web of Science ®Google Scholar
• Barlow JF, Faris RJ, Wang W, et al. Impact of specialty pharmacy on treatment costs for rheumatoid arthritis. Am J Pharm Benefits 2012;4(Special Issue):SP49-56
   Google Scholar
• Grijalva CG, Kaltenbach L, Arbogast PG, et al. Adherence to disease modifying anti-rheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Arthritis Care Res 2010;62:730-4
   Web of Science ®Google Scholar
• Oladapo A, Barner JC, Lawson KA, et al. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis. J Manag Care Pharm 2014;29:657-67
   Web of Science ®Google Scholar
• Li P, Blum MA, Feldt JV, et al. Adherence, discontinuation, and switching of biologic therapies in Medicaid enrollees with rheumatoid arthritis. Value Health 2010;13:805-12
   PubMed Web of Science ®Google Scholar
• Degli Esposti DL, Sangiorgi D, Perrone V, et al. Adherence & resource use among patients treated with biologic drugs: findings from BEETLE study. Clincoecon Outcomes Res 2014;6:401-7
   PubMedGoogle Scholar
• Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(6Suppl):S136-S43
   Web of Science ®Google Scholar
• Tkacz J, Ellis L, Bolge SC, et al. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 2014;36:737-47
   PubMed Web of Science ®Google Scholar
• de Thurah A, Norgaard M, Harder I, Stengaard-Pedersen K. Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective study. Rheumatol Int 2010;30:1441-8
   PubMed Web of Science ®Google Scholar
• Contreras-Yáñez I, Ponce de León S, Cabiedes J, et al. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 2010;340:282-90
   PubMed Web of Science ®Google Scholar
• Cannon GW, Mikuls TR, Hayden CL, et al. Merging veterans affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res 2011;63:1680-90
   PubMed Web of Science ®Google Scholar
• Waimann CA, Marengo MF, de Achaval S, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis. Consequences of low adherence. Arthritis Rheum 2013;65:1421-9
   PubMed Web of Science ®Google Scholar
• de Klerk E, van der Heijde D, Landewe R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872-8
   PubMed Web of Science ®Google Scholar
• Favalli EG, Marchesoni A, Colombo GL, Sinigaglia L. Pattern of use, economic burden and vial opimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 2008;26:45-51
   PubMed Web of Science ®Google Scholar
• Kaufmann J, Feist E, Roske AE. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 2013;32:1347-55
   PubMed Web of Science ®Google Scholar
• Kaneko A, Hirano Y, Fujibayashi T, et al. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. Mod Rheumatol 2013;23:466-77
   PubMed Web of Science ®Google Scholar
• Wong M, Mulherin D. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. Musculoskeletal Care 2007;5:148-59
   PubMedGoogle Scholar
• de Thurah A, Nørgaard M, Johansen MB, Stengaard-Pedersen K. Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. Scand J Rheumatol 2010;39:197-205
   PubMed Web of Science ®Google Scholar
• Raebel MA, Ellis J, Carroll NM, et al. Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 2011;27:57-64
   PubMed Web of Science ®Google Scholar
• Rolnick SJ, Pawloski PA, Hedblom BD, et al. Patient characteristics associated with medication adherence. Clin Med Res 2013;11:54-65
   PubMedGoogle Scholar
• Zhang Y, Lave JR, Donohue JM, et al. The impact of Medicare part D on medication adherence among older adults enrolled in Medicare-advantage products. Med Care 2010;48:409-17
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• Langley CA, Bush J. The Aston Medication Adherence Study: mapping the adherence patterns of an inner-city population. Int J Clin Pharm 2014;36:202-11
   PubMed Web of Science ®Google Scholar
• Hansen RA, Voils CI, Farley JF, et al. Prescriber continuity and medication adherence for complex patients. Ann Pharmacother 2015;49:293-302
   PubMed Web of Science ®Google Scholar
• Halava H, Korhonen MJ, Huupponen R, et al. Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities. CMAJ 2014;186:E449-56
   PubMed Web of Science ®Google Scholar
• White TJ, Chang E, Leslie S, et al. Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. J Man Care Pharm 2002;8:186-91
   Google Scholar
• Graversen L, Christensen B, Borch-Johnsen K, et al. Lipid-lowering drugs as primary prevention in general practice: do patients reach guideline goals and continue treatment? ADDITION Denmark. Scand J Prim Health Care 2011;29:216-21
   PubMed Web of Science ®Google Scholar
• Halava H, Westerlund H, Korhonen MJ, et al. Influence of retirement on adherence to statins in the insurance medicine all-Sweden total population data base. PLoS One 2015;10:e0130901
   PubMed Web of Science ®Google Scholar
• Beadles CA, Farley JF, Lichstein JC, et al. Do medical homes increase medication adherence for persons with multiple chronic conditions? Med Care 2015;53:168-76
   PubMed Web of Science ®Google Scholar
• Korhonen MJ, Halonen JI, Brookhart MA, et al. Childhood adversity as a predictor of non-adherence to statin therapy in adulthood. PLoS One 2015;10:e0127638
   PubMed Web of Science ®Google Scholar
• Latry P, Molimard M, Dedieu B, et al. Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC Cardiovasc Disord 2011;11:46
   PubMed Web of Science ®Google Scholar
• Kalia NK, Cespedes L, Youssef G, et al. Motivational effects of coronary artery calcium scores on statin adherence and weight loss. Coron Artery Dis 2015;26:225-30
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacother 2008;28:437-43
   PubMed Web of Science ®Google Scholar
• Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organisation enrollees with dyslipidemia. Clin Ther 2005;27:1639-46
   PubMed Web of Science ®Google Scholar
• Rannanheimo PK, Tittanen P, Hartikainen J, et al. Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in Finland. Value Health 2015;18:896-905
   PubMed Web of Science ®Google Scholar
• Corrao G, Conti V, Merlino L, et al. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 2010;32:300-10
   PubMed Web of Science ®Google Scholar
• Mann DM, Allegrante JP, Natarajan S, et al. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007;21:311-16
   PubMed Web of Science ®Google Scholar
• Batal HA, Krantz M, Dale RA, et al. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res 2007;7:175
   PubMed Web of Science ®Google Scholar
• Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv Ther 2005;22:163-71
   PubMed Web of Science ®Google Scholar
• Stilley CS, Sereika S, Muldoon MF, et al. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-24
   PubMed Web of Science ®Google Scholar
• Riesen WF, Noll G, Dariolo R; on behalf of the ORBITAL trialists. Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia. Swiss Med Weekly 2008;138:420-6
   PubMed Web of Science ®Google Scholar
• Deambrosis P, Saramin C, Terrazzani G, et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 2007;63:197-203
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Rodriquez-Lozano C, Campos-Fernandez C, et al; on behalf of the BIOBADASER 2.0 Study Group. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012;71:382-5
   PubMed Web of Science ®Google Scholar
• Viller F, Guillemin F, Briancon S, et al. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 1999;26:2114-22
   PubMed Web of Science ®Google Scholar
• Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Should we target patients with the most to gain? J Gen Intern Med 2004;19:638-45
   Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22
   PubMed Web of Science ®Google Scholar
• Nanau RM, Neuman MG. Safety of anti-tumour necrosis factor therapies in arthritis patients. J Pharm Pharm Sci 2014;17:324-61
   PubMed Web of Science ®Google Scholar
• Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials. Circ Cardioavsc Qual Outcomes 2013;6:390-9
   PubMed Web of Science ®Google Scholar